drugset / Trial / NCT01072890
Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors
Phase 1
Completed
8 enrolled
University of California, Davis
GlaxoSmithKline · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety of temsirolimus and pazopanib at different doses. Patients who have an advanced cancer that is not felt to benefit from standard treatment or are no longer responding to other treatment will be asked to take part in this study. The study hypothesis is that temsirolimus and pazopanib can be administered safely in combination and that combined targeting of the mammalian target of rapamycin (mTOR) and vascular endothelial growth factor receptor (VEGFR) signaling pathways will be effective in treating patients with advanced solid tumors.
Timeline
- Start
- 2010-02
- Primary completion
- 2012-02
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pazopanib | Small molecule | 200 mg | Oral |
| Subject | Pazopanib | Small molecule | 400 mg | Oral |
| Subject | Temsirolimus | Small molecule | 10 mg | Intravenous |
| Subject | Temsirolimus | Small molecule | 15 mg | Intravenous |